Egetis Therapeutics AB (publ) (EGTX) — Working Capital to Net Assets Ratio
Egetis Therapeutics AB (publ) (EGTX) has a Working Capital to Net Assets ratio of -29.6% as of March 2026. Working capital of Skr-73.60 Million (current assets of Skr163.20 Million minus current liabilities of Skr236.80 Million) is measured against net assets of Skr248.70 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Egetis Therapeutics AB (publ) liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Egetis Therapeutics AB (publ) Working Capital to Net Assets (2008–2025)
This chart shows how Egetis Therapeutics AB (publ)'s Working Capital to Net Assets ratio has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the ratio stands at -29.6%, reflecting working capital of Skr-73.60 Million against net assets of Skr248.70 Million SEK. For the complete balance sheet picture, see EGTX total asset value.
Annual Working Capital to Net Assets for Egetis Therapeutics AB (publ) (2008–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Egetis Therapeutics AB (publ) from 2008 to 2025, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read how much debt does Egetis Therapeutics AB (publ) carry for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 3.7% | Skr12.70 Million | Skr338.70 Million | Skr253.60 Million | Skr240.90 Million | ▼ -31.9 pp |
| 2024 | 35.7% | Skr175.90 Million | Skr492.90 Million | Skr380.10 Million | Skr204.20 Million | ▼ -8.7 pp |
| 2023 | 44.4% | Skr242.00 Million | Skr545.60 Million | Skr345.90 Million | Skr103.90 Million | ▲ +25.0 pp |
| 2022 | 19.4% | Skr98.00 Million | Skr506.20 Million | Skr147.40 Million | Skr49.40 Million | ▼ -2.2 pp |
| 2021 | 21.6% | Skr113.73 Million | Skr527.04 Million | Skr152.90 Million | Skr39.17 Million | ▼ -14.9 pp |
| 2020 | 36.5% | Skr229.73 Million | Skr629.63 Million | Skr299.87 Million | Skr70.14 Million | ▼ -63.5 pp |
| 2019 | 100.0% | Skr244.87 Million | Skr244.88 Million | Skr269.95 Million | Skr25.08 Million | ▼ 0.0 pp |
| 2018 | 100.0% | Skr219.36 Million | Skr219.36 Million | Skr242.04 Million | Skr22.68 Million | ▲ +0.0 pp |
| 2017 | 100.0% | Skr303.71 Million | Skr303.71 Million | Skr315.37 Million | Skr11.66 Million | ▲ +0.0 pp |
| 2016 | 100.0% | Skr389.56 Million | Skr389.56 Million | Skr396.44 Million | Skr6.87 Million | ▼ 0.0 pp |
| 2015 | 100.0% | Skr48.03 Million | Skr48.03 Million | Skr52.36 Million | Skr4.33 Million | ▲ +0.1 pp |
| 2014 | 99.9% | Skr90.61 Million | Skr90.66 Million | Skr103.42 Million | Skr12.81 Million | ▲ +0.1 pp |
| 2013 | 99.9% | Skr46.90 Million | Skr46.95 Million | Skr50.96 Million | Skr4.06 Million | ▼ 0.0 pp |
| 2012 | 99.9% | Skr53.88 Million | Skr53.94 Million | Skr60.40 Million | Skr6.52 Million | ▼ -0.1 pp |
| 2011 | 100.0% | Skr87.52 Million | Skr87.53 Million | Skr91.41 Million | Skr3.89 Million | ▲ +110.1 pp |
| 2010 | -10.1% | Skr-705.58K | Skr6.99 Million | Skr796.90K | Skr1.50 Million | ▼ -13.4 pp |
| 2009 | 3.3% | Skr187.92K | Skr5.64 Million | Skr461.90K | Skr273.98K | ▼ -6.6 pp |
| 2008 | 9.9% | Skr500.00K | Skr5.05 Million | Skr823.56K | Skr323.55K | — |